• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CAR T-Cell Therapy for Refractory Posttransplantation Lymphoproliferative Disorder in a Kidney Transplant Patient.

作者信息

Guy Pierre, Marion Olivier, Oberic Lucie, Darres Amandine, Cointault Olivier, Del Bello Arnaud, Kamar Nassim

机构信息

Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France.

Department of Hematology, IUCT, Toulouse University Hospital, Toulouse, France.

出版信息

Transplant Direct. 2024 Feb 26;10(3):e1584. doi: 10.1097/TXD.0000000000001584. eCollection 2024 Mar.

DOI:10.1097/TXD.0000000000001584
PMID:38414975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10898664/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c2/10898664/1f6332bc90d2/txd-10-e1584-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c2/10898664/b7e76955605d/txd-10-e1584-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c2/10898664/dd77c2609dbd/txd-10-e1584-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c2/10898664/1f6332bc90d2/txd-10-e1584-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c2/10898664/b7e76955605d/txd-10-e1584-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c2/10898664/dd77c2609dbd/txd-10-e1584-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c2/10898664/1f6332bc90d2/txd-10-e1584-g003.jpg

相似文献

1
CAR T-Cell Therapy for Refractory Posttransplantation Lymphoproliferative Disorder in a Kidney Transplant Patient.肾移植患者难治性移植后淋巴细胞增生性疾病的嵌合抗原受体T细胞疗法
Transplant Direct. 2024 Feb 26;10(3):e1584. doi: 10.1097/TXD.0000000000001584. eCollection 2024 Mar.
2
CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.嵌合抗原受体 T 细胞疗法治疗移植后难治性淋巴增殖性疾病的实体器官移植受者。
Am J Transplant. 2021 Feb;21(2):809-814. doi: 10.1111/ajt.16367. Epub 2020 Dec 5.
3
Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD).嵌合抗原受体 (CAR) T 细胞治疗移植后淋巴组织增生性疾病 (PTLD) 的肾移植患者。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2216116. doi: 10.1080/21645515.2023.2216116. Epub 2023 Jun 6.
4
Initial spontaneous remission of posttransplantation Epstein Barr virus-related B-cell lymphoproliferative disorder of the skin in a renal transplant recipient: case report and review of the literature on cutaneous B-cell posttransplantation lymphoproliferative disease.肾移植受者皮肤移植后爱泼斯坦-巴尔病毒相关B细胞淋巴增殖性疾病的初始自发缓解：病例报告及皮肤移植后B细胞淋巴增殖性疾病文献综述
Am J Dermatopathol. 2002 Oct;24(5):414-22. doi: 10.1097/00000372-200210000-00008.
5
Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report.抗CD19嵌合抗原受体T细胞疗法治疗伴有11q畸变的难治性侵袭性伯基特样淋巴瘤后发生的肾移植T细胞介导的排斥反应：一例报告
Am J Kidney Dis. 2022 May;79(5):760-764. doi: 10.1053/j.ajkd.2021.07.012. Epub 2021 Aug 27.
6
Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series.抗 CD19 CAR-T 疗法治疗 EBV 阴性移植后淋巴组织增生性疾病：单中心病例系列。
Bone Marrow Transplant. 2021 May;56(5):1031-1037. doi: 10.1038/s41409-020-01145-1. Epub 2020 Nov 23.
7
Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.肾移植受者接受嵌合抗原受体T细胞疗法治疗B细胞淋巴瘤后发生急性肾损伤
Kidney Med. 2021 May 28;3(4):665-668. doi: 10.1016/j.xkme.2021.03.011. eCollection 2021 Jul-Aug.
8
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.CD19 CAR-T 细胞治疗复发/难治性实体器官移植相关 PTLD 的安全性和生存的真实世界证据。
Br J Haematol. 2023 Jul;202(2):248-255. doi: 10.1111/bjh.18828. Epub 2023 May 2.
9
Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.抗CD19嵌合抗原受体T细胞联合程序性细胞死亡蛋白1抑制剂治疗难治性移植后淋巴细胞增生性疾病患者的安全性和有效性：病例报告及文献综述
Front Oncol. 2021 Sep 16;11:726134. doi: 10.3389/fonc.2021.726134. eCollection 2021.
10
Posttransplantation lymphoproliferative disorder in cardiac transplant allografts.
Ann Thorac Surg. 1997 Dec;64(6):1822-4. doi: 10.1016/s0003-4975(97)01044-8.

引用本文的文献

1
Nephrology's Next Frontier: Expanding the Reach of CAR T-Cell Therapy for Refractory Lupus Nephritis and Beyond.肾脏病学的下一个前沿领域：扩大嵌合抗原受体T细胞疗法在难治性狼疮性肾炎及其他疾病中的应用范围
Indian J Nephrol. 2025 Jul-Aug;35(4):456-459. doi: 10.25259/IJN_274_2024. Epub 2024 Dec 11.
2
Application of novel CAR technologies to improve treatment of autoimmune disease.新型 CAR 技术在改善自身免疫性疾病治疗中的应用。
Front Immunol. 2024 Oct 9;15:1465191. doi: 10.3389/fimmu.2024.1465191. eCollection 2024.

本文引用的文献

1
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.CD19 CAR-T 细胞治疗复发/难治性实体器官移植相关 PTLD 的安全性和生存的真实世界证据。
Br J Haematol. 2023 Jul;202(2):248-255. doi: 10.1111/bjh.18828. Epub 2023 May 2.
2
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.有效的桥接治疗可以改善大 B 细胞淋巴瘤患者的 CD19 CAR-T 治疗效果，同时保持安全性。
Blood Adv. 2023 Jun 27;7(12):2872-2883. doi: 10.1182/bloodadvances.2022009019.
3
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD.
成功应用嵌合抗原受体T细胞疗法治疗一名患有难治性移植后淋巴增殖性疾病的心脏和肾脏移植受者。
JACC CardioOncol. 2022 Dec 20;4(5):713-716. doi: 10.1016/j.jaccao.2022.09.002. eCollection 2022 Dec.
4
CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review.实体器官移植受者发生移植后淋巴细胞增生性疾病的CAR-T治疗：病例报告及文献综述
Curr Res Transl Med. 2021 Oct;69(4):103304. doi: 10.1016/j.retram.2021.103304. Epub 2021 Jul 22.
5
Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.抗 CD19 嵌合抗原受体 T 细胞疗法成功治疗肝移植后小儿难治性 Burkitt 淋巴瘤 PTLD。
Cell Transplant. 2021 Jan-Dec;30:963689721996649. doi: 10.1177/0963689721996649.
6
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.皮质类固醇对嵌合抗原受体 T 细胞疗法治疗大 B 细胞淋巴瘤疗效的预后影响。
Blood. 2021 Jun 10;137(23):3272-3276. doi: 10.1182/blood.2020008865.
7
Safety of CAR T-cell therapy in kidney transplant recipients.肾移植受者中CAR T细胞疗法的安全性。
Blood. 2021 May 6;137(18):2558-2562. doi: 10.1182/blood.2020008759.
8
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.免疫检查点抑制剂在肾移植癌症患者中的安全性和疗效的多中心研究。
Kidney Int. 2021 Jul;100(1):196-205. doi: 10.1016/j.kint.2020.12.015. Epub 2020 Dec 24.
9
Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series.抗 CD19 CAR-T 疗法治疗 EBV 阴性移植后淋巴组织增生性疾病：单中心病例系列。
Bone Marrow Transplant. 2021 May;56(5):1031-1037. doi: 10.1038/s41409-020-01145-1. Epub 2020 Nov 23.
10
CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.嵌合抗原受体 T 细胞疗法治疗移植后难治性淋巴增殖性疾病的实体器官移植受者。
Am J Transplant. 2021 Feb;21(2):809-814. doi: 10.1111/ajt.16367. Epub 2020 Dec 5.